Giant Biogene - Public Comps and Valuation Multiples

Giant Biogene Overview

About Giant Biogene

Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.

Founded

2021

HQ

Employees

1.8K+

Website

xajuzi.com

Sectors

Health & Beauty

Financials

LTM Revenue $998M

LTM EBITDA $417M

EV

$4.0B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Giant Biogene Financials

As of November 2025, Giant Biogene reported last 12-month revenue of $998M and EBITDA of $417M.

In the same period, Giant Biogene generated $806M in LTM gross profit and $356M in net income.

See Giant Biogene valuation multiples based on analyst estimates

Giant Biogene P&L

In the most recent fiscal year, Giant Biogene reported revenue of $712M and EBITDA of $322M.

Giant Biogene expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Giant Biogene valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$998M	XXX	$712M	XXX	XXX	XXX
Gross Profit	$806M	XXX	$584M	XXX	XXX	XXX
Gross Margin	81%	XXX	82%	XXX	XXX	XXX
EBITDA	$417M	XXX	$322M	XXX	XXX	XXX
EBITDA Margin	42%	XXX	45%	XXX	XXX	XXX
EBIT	$400M	XXX	$297M	XXX	XXX	XXX
EBIT Margin	40%	XXX	42%	XXX	XXX	XXX
Net Profit	$356M	XXX	$265M	XXX	XXX	XXX
Net Margin	36%	XXX	37%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Giant Biogene including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $998M. EBITDA for the last twelve months was $417M. In the most recent fiscal year, Giant Biogene achieved $712M in revenue and $322M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$998M	Analyst estimates available to subscribers	$712M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$806M	Analyst estimates available to subscribers	$584M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	80.8% gross margin	Analyst estimates available to subscribers	82.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$417M	Analyst estimates available to subscribers	$322M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	41.8% EBITDA margin	Analyst estimates available to subscribers	45.3% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$400M	Analyst estimates available to subscribers	$297M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	40.0% EBIT margin	Analyst estimates available to subscribers	41.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$356M	Analyst estimates available to subscribers	$265M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	35.7% net profit margin	Analyst estimates available to subscribers	37.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Giant Biogene

This financial data table provides comprehensive performance metrics for Giant Biogene, a company based in Hong Kong. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Giant Biogene generated $998M in revenue over the last twelve months.
The company achieved $417M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $806M.
Net income over the last twelve months reached $356M.

Fiscal Year Performance

In the most recent fiscal year, Giant Biogene reported $712M in total revenue.
Fiscal year EBITDA was $322M.
The company maintained a gross profit margin of 82.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 45.3%.
Net profit margin reached 37.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Giant Biogene. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Giant Biogene Stock Performance

Giant Biogene has current market cap of HKD 40.5B (or $5.2B), and EV of HKD 30.8B (or $4.0B).

Market Cap Evolution

Giant Biogene Stock Data

As of December 5, 2025, Giant Biogene's stock price is HKD 38 (or $5).

See Giant Biogene trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$4.0B	$5.2B	XXX	XXX	XXX	XXX	$0.31

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Giant Biogene Valuation Multiples

Giant Biogene's trades at 5.6x EV/Revenue multiple, and 12.3x EV/EBITDA.

See valuation multiples for Giant Biogene and 15K+ public comps

Giant Biogene Financial Valuation Multiples

As of December 5, 2025, Giant Biogene has market cap of $5.2B and EV of $4.0B.

Equity research analysts estimate Giant Biogene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Giant Biogene has a P/E ratio of 16.1x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$5.2B	XXX	$5.2B	XXX	XXX	XXX
EV (current)	$4.0B	XXX	$4.0B	XXX	XXX	XXX
EV/Revenue	4.4x	XXX	5.6x	XXX	XXX	XXX
EV/EBITDA	10.4x	XXX	12.3x	XXX	XXX	XXX
EV/EBIT	10.9x	XXX	13.3x	XXX	XXX	XXX
EV/Gross Profit	5.4x	XXX	n/a	XXX	XXX	XXX
P/E	16.1x	XXX	19.6x	XXX	XXX	XXX
EV/FCF	16.6x	XXX	17.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Giant Biogene Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Giant Biogene Margins & Growth Rates

Giant Biogene's last 12 month revenue growth is 23%

Giant Biogene's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Giant Biogene's rule of 40 is 73% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Giant Biogene's rule of X is 98% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Giant Biogene and other 15K+ public comps

Giant Biogene Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	23%	XXX	26%	XXX	XXX	XXX
EBITDA Margin	42%	XXX	45%	XXX	XXX	XXX
EBITDA Growth	19%	XXX	29%	XXX	XXX	XXX
Rule of 40	73%	XXX	68%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	98%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	36%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	2%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	40%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial